Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients
Status:
Not yet recruiting
Trial end date:
2024-10-31
Target enrollment:
Participant gender:
Summary
Prograf and Envarsus are two different formulations of Tacrolimus which is used as an
immunosuppressant in liver transplant (LT) patients. Prograf is currently used as part of the
standard immunosuppression regimen for LT recipients at UHN. This study will compare the use
of Prograf and Envarsus and their effects on liver and renal function, trough tacrolimus
levels, drug-related adverse effects, and patient adherence. Trial design is a pilot
randomized trial. The study aims to recruit 40 patients from UHN's LT program and they will
be randomized 1:1 to either stay on their current dose of Prograf or be converted to a
once-daily equivalent dose of Envarsus. Both groups of patients will be followed for 48
weeks. This study will compare the change from baseline to week 48 in liver and renal
function, tacrolimus-related side effects and patient reported outcomes between the two study
groups.